DISCLOSURES

K. Nearing reports no disclosures. J.W. Tsao serves on the editorial board of *Neurology: Clinical Practice*; receives publishing royalties for *Traumatic Brain Injury: A Clinician's Guide to Diagnosis, Management, and Rehabilitation* (Springer, 2012) and *Teleneurology in Practice: A Comprehensive Clinical Guide* (Springer, 2015); and owns stock in Biogen and Illumina. Full disclosure form information provided by the author is available with the **full text of this article at [Neurology.org/cp](https://www.neurology.org/cp)**.

CORRECTIONS

Pimavanserin: A novel therapeutic option for Parkinson disease psychosis

In the Review article “Pimavanserin: A novel therapeutic option for Parkinson disease psychosis” by T. Hawkins and B.D. Berman,¹ there are 2 minor errors. The last sentence in the third paragraph under “Development of pimavanserin” should have read “In addition, pimavanserin did not affect motor symptom severity and led to significant decreases in caregiver burden and improvements in nighttime sleep and daytime wakefulness.” The second-to-last sentence under “Prescribing information” should read “In the positive phase 3 trial of pimavanserin detailed above, there were 3 deaths; 2 in the treatment group and 1 in the placebo group.” The authors regret the errors.

REFERENCE

1. Hawkins T, Berman BD. Pimavanserin: A novel therapeutic option for Parkinson disease psychosis. *Neurol Clin Pract* 2017;7:157–162.

Acute hemichorea as unusual first multiple sclerosis presentation

In the article “Acute hemichorea as unusual first multiple sclerosis presentation” by G. Giovannini et al.¹, published ahead of print on July 22, 2016, there was an error in Video 1. An audio track should not have been included in the video. The revised video without the audio track was republished on June 27, 2017. The authors regret the error.

REFERENCE

1. Giovannini G, Cavallieri F, Meletti S, et al. Acute hemichorea as unusual first multiple sclerosis presentation. *Neurol Clin Pract* 2017;7:e9–e11.

Neurology® Clinical Practice

Pimavanserin: A novel therapeutic option for Parkinson disease psychosis

Neurol Clin Pract 2017;7;282

DOI 10.1212/CPJ.0000000000000380

This information is current as of August 14, 2017

Updated Information & Services

including high resolution figures, can be found at:
<http://cp.neurology.org/content/7/4/282.1.full.html>

References

This article cites 1 articles, 1 of which you can access for free at:
<http://cp.neurology.org/content/7/4/282.1.full.html##ref-list-1>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
<http://cp.neurology.org/misc/about.xhtml#permissions>

Reprints

Information about ordering reprints can be found online:
<http://cp.neurology.org/misc/addir.xhtml#reprintsus>

Neurol Clin Pract is an official journal of the American Academy of Neurology. Published continuously since 2011, it is now a bimonthly with 6 issues per year. Copyright © 2017 American Academy of Neurology. All rights reserved. Print ISSN: 2163-0402. Online ISSN: 2163-0933.